Breast Cancer

Abigail S. Caudle, MD, Assistant Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, describes the ACOSOG Z1071 study in breast cancer.

Patrick Borgen, MD, from the Maimonides Breast Cancer Center, details the factors that go into a patient's decision to undergo a mastectomy.

Gunter von Minckwitz, MD, PhD, Chairman, German Breast Group, Professor of Gynecology, University of Frankfurt, Germany, discusses pathologic complete response (pCR) and outcomes.

This year marks the 30th Annual Miami Breast Cancer Conference, a milestone for Daniel A. Osman, MD, and his wife Lois, who together launched the gathering in 1983 with fewer than 100 attendees and a focus on the then relatively new domain of lumpectomies in breast cancer treatment.

Hyman B. Muss, MD, Professor of Medicine, Director of Geriatric Oncology, Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill School of Medicine, on the need for geriatric assessments.

The FDA approved the radioactive diagnostic imaging agent technetium Tc 99m tilmanocept (Lymphoseek Injection) to identify lymph nodes for potential removal in patients with breast cancer or melanoma.

Anees Chagpar, MD, MSc, MA, MPH, Associate Professor of Surgery (Oncology), Director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, discusses the need for repeat biopsy in patients with breast cancer.

Donna Shalala, PhD, President, University of Miami, discusses the new healthcare reform in the U.S.

Physicians wondering how the Affordable Care Act (ACA) will impact their practices heard a robust defense of the new law from Donna E. Shalala, PhD, on Saturday.

Martine Piccart, MD, PhD, discusses the implications of the HERA trial, which looked at two years compared with one year of trastuzumab after adjuvant chemotherapy in women with HER2-positive breast cancer.

As the genomic era in oncology unfolds, the development of new therapeutics increasingly will involve targeting a range of mutations simultaneously, requiring a "next-generation clinical trials system" to match the advances that technology is delivering.

Two large clinical trials are expected to define the impact that employing genomic tests in treatment decisions has on survival outcomes, according to Martine J. Piccart, MD, PhD.

Oncology leaders are bracing for a host of changes in the healthcare system, not only as a result of the recently upheld insurance reform legislation but also because of continued pressure to control the ever-rising cost of cancer care.

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the field of psycho-oncology.

Ron Bose, MD, PhD, from the Siteman Cancer Center, discusses the prevalence of HER2 gene mutations in patients diagnosed with breast cancer.

Burnout is described as a syndrome of "emotional exhaustion, depersonalization, and feelings of low personal accomplishment," and is an increasingly problematic condition among physicians for a multitude of reasons.

Hope S. Rugo, MD, at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the standard for front-line chemotherapy in patients with breast cancer.

An interview with Debu Tripathy, MD, summarizing noteworthy results from the 2012 ASCO Annual Meeting and SABCS, including clinical studies in local, adjuvant, and metastatic breast cancer therapies.

Richard Finn, MD, from Jonsson Comprehensive Cancer Center, discusses the rationale for targeting cyclin-dependent kinases 4 and 6 with the novel agent PD 0332991 in breast cancer.

Johanna Bendell, MD, Director of GI Cancer Research Program, Associate Director, Drug Development Program, Sarah Cannon Research Institute, discusses the inhibition of heat shock protein 90 (Hsp90) in advanced solid tumors.

Justin M. Balko, PharmD, PhD, from the Vanderbilt-Ingram Cancer Center, describes a study that discovered JAK2 alterations in patients with treatment-refractory triple-negative breast cancer.

Linda T. Vahdat, MD, from the Weill Cornell Medical College, discusses the combination of eribulin mesylate and trastuzumab as a first-line therapy for HER2-positive metastatic breast cancer.

The FDA has approved ado-trastuzumab emtansine, also known as T-DM1, for HER2-positive metastatic breast cancer.

Genetic or drug-induced alterations of the enzyme CYP2D6 that result in reduced metabolism of tamoxifen are associated with a higher risk of recurrence and death in women with ER–positive breast cancer who receive the drug.

Christopher Twelves, MD, Professor and Honorary Consultant in Medical Oncology, University of Leeds, highlights key findings from the 2012 San Antonio Breast Cancer Symposium, which took place in December 2012.